{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:37:37Z","timestamp":1793522257291,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015699","name":"Fresenius Medical Care North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.kint.2022.08.012","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T05:00:08Z","timestamp":1664773208000},"page":"974-989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":325,"title":["Diabetes management in chronic kidney disease: a\u00a0consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)"],"prefix":"10.1016","volume":"102","author":[{"given":"Ian H.","family":"de Boer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Sadusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie M.","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia E.","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl. 1","key":"10.1016\/j.kint.2022.08.012_bib1","first-page":"S1","article-title":"Standards of Medical Care in Diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"issue":"4S","key":"10.1016\/j.kint.2022.08.012_bib2","first-page":"S1","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.012_bib4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2022.08.012_bib5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.08.012_bib6","series-title":"2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","year":"2020"},{"key":"10.1016\/j.kint.2022.08.012_bib7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.08.012_bib8","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.08.012_bib9","series-title":"National Diabetes Statistics Report, 2020","year":"2020"},{"key":"10.1016\/j.kint.2022.08.012_bib10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.ajkd.2020.01.007","article-title":"Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. CKD awareness among US adults by future risk of kidney failure","volume":"76","author":"Chu","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.08.012_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.kint.2022.08.012_bib12","first-page":"320","article-title":"American Diabetes Association Standards of Medical Care in Diabetes 2017","volume":"9","author":"Marathe","year":"2017","journal-title":"J\u00a0Diabetes"},{"key":"10.1016\/j.kint.2022.08.012_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108072","article-title":"Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"162","author":"Williams","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.kint.2022.08.012_bib14","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc20-0072","article-title":"Health care costs associated with macrovascular, microvascular, and metabolic complications of type 2 diabetes across time: estimates from a population- based cohort of more than 0.8 million individuals with up to 15 years of follow-up","volume":"43","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2337\/dc19-2137","article-title":"The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study","volume":"43","author":"Wan","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.012_bib17","first-page":"S175","article-title":"11. Chronic kidney disease and risk management: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.012_bib19","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A\u00a0unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.08.012_bib21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/ki.2013.500","article-title":"The accuracy of predicting cardiovascular death based on one compared to several albuminuria values","volume":"85","author":"Hatlen","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.012_bib22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib23","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2022.08.012_bib24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJMoa2103753","article-title":"Race, genetic ancestry, and estimating kidney function in CKD","volume":"385","author":"Hsu","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2022.08.012_bib26","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"suppl 2","key":"10.1016\/j.kint.2022.08.012_bib27","first-page":"S12","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2022.08.012_bib28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.kint.2019.09.020","article-title":"Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study","volume":"97","author":"Townsend","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.012_bib29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.kint.2020.08.039","article-title":"Rationale and design of the Kidney Precision Medicine Project","volume":"99","author":"de Boer","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.012_bib30","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.012_bib31","first-page":"S60","article-title":"5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2215\/CJN.10270620","article-title":"Integrating patient priorities with science by community engagement in the Kidney Precision Medicine Project","volume":"16","author":"Tuttle","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.08.012_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2215\/CJN.18191120","article-title":"The patient voice in health care decision making: the perspective of people living with diabetes and CKD","volume":"16","author":"Sadusky","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.012_bib34","first-page":"S46","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib35","series-title":"Protein and Amino Acid Requirements in Human Nutrition","year":"2007"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.012_bib36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.012_bib37","first-page":"S97","article-title":"7. Diabetes technology: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"issue":"3S","key":"10.1016\/j.kint.2022.08.012_bib39","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.012_bib40","first-page":"S144","article-title":"10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib41","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.2018.0642","article-title":"Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC\/AHA recommendations","volume":"319","author":"de Boer","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2022.08.012_bib42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib43","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","article-title":"The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study","volume":"63","author":"Keane","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.012_bib44","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: s multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2022.08.012_bib46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline\u00a0for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2022.08.012_bib47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.kint.2022.08.012_bib48","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.08.012_bib49","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000080241","article-title":"Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics","volume":"27","author":"Wanner","year":"2004","journal-title":"Kidney Blood Press Res"},{"issue":"suppl 1","key":"10.1016\/j.kint.2022.08.012_bib51","first-page":"S1","article-title":"Introduction: Standards of Medical Care in Diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib52","series-title":"Glucophage [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, 2018","year":"2018"},{"key":"10.1016\/j.kint.2022.08.012_bib53","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2022.08.012_bib54","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib55","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.08.012_bib57","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib59","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR\u00a0<30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.08.012_bib60","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.08.012_bib61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ehjcvp\/pvac001","article-title":"SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis","volume":"8","author":"Razuk","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.kint.2022.08.012_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101163","article-title":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials","volume":"41","author":"Staplin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.kint.2022.08.012_bib64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.18881220","article-title":"SGLT2 inhibitors in diabetic kidney disease","volume":"16","author":"Zoungas","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.08.012_bib65","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fphar.2019.01066","article-title":"Appraisal of non-cardiovascular safety for sodium-glucose cotransporter 2 inhibitors: a systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"10","author":"Shi","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kint.2022.08.012_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.kint.2022.08.012_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.08.012_bib68","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2022.08.012_bib69","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.kint.2022.08.012_bib70","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib71","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.08.012_bib72","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib74","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib75","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib76","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib77","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.kint.2022.08.012_bib78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.disamonth.2009.12.009","article-title":"Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting","volume":"56","author":"Hahr","year":"2010","journal-title":"Dis Mon"},{"key":"10.1016\/j.kint.2022.08.012_bib79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2337\/dc15-0858","article-title":"Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005\u20132011","volume":"39","author":"Pathak","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib80","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","article-title":"Use of empagliflozin in recipients of kidney transplant: a report of 8 cases","volume":"51","author":"Attallah","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2022.08.012_bib81","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000885","article-title":"Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients","volume":"5","author":"Cehic","year":"2019","journal-title":"Transplant Direct"},{"key":"10.1016\/j.kint.2022.08.012_bib82","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.kint.2022.08.012_bib83","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kint.2022.08.012_bib84","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2022.08.012_bib85","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2022.08.012_bib86","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib87","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events With finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2022.08.012_bib88","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2022.08.012_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822006342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253822006342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:29:02Z","timestamp":1793503742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253822006342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0085253822006342"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2022.08.012","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes management in chronic kidney disease: a\u00a0consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2022.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}